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Abstract 
A four-year-old boy presented with non-immune hemolysis, thrombocytopenia and acute 
kidney injury. Investigations for an underlying etiology failed to identify a definitive cause 
and a putative diagnosis of complement-mediated atypical hemolytic uremic syndrome 
(aHUS) was made. The patient was commenced initially on plasma exchange and 
subsequently eculizumab, after which his renal function rapidly improved. Whilst on 
eculizumab, despite adequate complement blockade, he represented twice with hemolytic 
anemia and thrombocytopenia, but without renal involvement. Genetic analysis did not 
uncover a mutation in any known aHUS gene (CFH, CFI, CFB, C3, CD46, THBD, INF2 and 
DGKE) and anti-factor H antibodies were negative. Whole exome sequencing was 
undertaken to identify a cause for the eculizumab resistance, this revealed a pathogenic 
variant in G6PD (Glucose 6 Phosphate Dehydrogenase); which was confirmed by functional 
analysis demonstrating decreased erythrocyte G6PD activity levels. Eculizumab was 
withdrawn. Complement-mediated aHUS is a diagnosis of exclusion and this case highlights 
the diagnostic difficulty that remains without an immediately available biomarker for 
confirmation. This case of G6PD deficiency presented with a phenotype clinically 
indistinguishable from complement-mediated aHUS. We recommend G6PD deficiency is 
included in the differential diagnosis of patients presenting with aHUS and suggest measuring 
erythrocyte G6PD levels in these patients. 
 
Keywords: atypical hemolytic uremic syndrome (aHUS), Glucose 6 Phosphate 
Dehydrogenase (G6PD), eculizumab, chronic non-spherocytic hemolytic anemia 
(CNSHA)  
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Introduction 
Inherited or acquired dysregulation of the alternative complement pathway have been 
demonstrated to predispose to many cases of atypical hemolytic uremic syndrome 
(aHUS)(MIM 235400)1. This understanding of the pathogenesis of aHUS ultimately resulted 
in the successful introduction of the complement inhibitor eculizumab into the clinic2.  
The term primary aHUS has been used when an underlying defect in the complement system 
is suspected (mutations in CFH, CFI, CFB, C3, CD46, or anti factor H antibodies) and 
secondary aHUS where there is another cause (e.g. infection associated, bone marrow 
transplant associated, drug-induced, cobalamin C disease etc.)3. Complicating such a 
classification is the finding that, in many cases a trigger (e.g. infection) is required for disease 
to manifest in those with a complement abnormality1. No biomarker exists that will confirm 
the diagnosis of a primary complement mediated aHUS in the acute setting and the diagnosis 
is therefore one of exclusion. Early initiation of eculizumab has been shown to lead to better 
outcomes2. Thus, treatment with eculizumab is often commenced in patients with suspected 
primary complement mediated aHUS, and discontinued if an alternative etiology is 
subsequently identified. 
With the increasing use of eculizumab in clinical practice, it has become apparent that there 
are subgroups of non-complement mediated aHUS that do not respond to eculizumab (e.g. 
DGKE 4 and INF2 5). Additionally, a rare polymorphism in C5 has been demonstrated to 
impair eculizumab efficacy6. 
Here we describe a child presenting with non-immune hemolysis, thrombocytopenia and 
acute kidney injury (AKI) who relapsed whilst on eculizumab and did not carry genetic risk 
factors for eculizumab non-response. Using whole exome sequencing we identified a 
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pathogenic variant in G6PD (c.1160G>A, pR387H) that caused a phenotype 
indistinguishable from aHUS. 
Case Presentation 
A four-year-old boy presented to his local hospital with coryzal symptoms and macroscopic 
hematuria, having been treated with trimethoprim for a presumed UTI one week previously. 
On presentation, he was profoundly anemic (hemoglobin 40g/L), with evidence of non-
immune intravascular hemolysis (direct coombs test negative, lactate dehydrogenase (LDH) 
1590U/L, undetectable haptoglobins) and acute kidney injury (creatinine 3.3mg/dL) (figure 
1), urinalysis demonstrated dipstick positive hemoglobin and  numerous red blood cells on 
microscopy. He required transfusion with packed red blood cells and was transferred to the 
regional nephrology center. There was continued evidence of hemolysis (maximum LDH 
9000U/L), further deterioration of renal function (maximum creatinine 5.4mg/dL with 
oliguria and fluid overload, necessitating one session of hemodialysis) and thrombocytopenia 
(platelets 94x109/L). His initial investigations ruled out shiga toxin HUS (negative E.coli 
culture and serology), thrombotic thrombocytopenic purpura (ADAMSTS13, 113%) and 
other causes of aHUS (normal homocysteine levels, negative anti-nuclear antibodies, 
negative HIV serology, negative T-antigen, and negative cold agglutinins). Complement 
levels were normal (C3 1.22mg/L, C4 0.24mg/L) 
A presumptive diagnosis of primary complement-mediated aHUS was made and he was 
commenced on plasma exchange (PEX).  Following initiation of PEX his renal function, 
hemoglobin, LDH, and platelets improved (figure 1). Six weeks following presentation he 
was commenced on eculizumab (600mg day 1 and 7, 300mg day 9, 300mg every fortnight 
thereafter) and PEX was discontinued.  
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Shortly after starting eculizumab, he contracted metapneumovirus and presented with acute 
deterioration of his hematological parameters (hemoglobin 77g/L, LDH 2248U/L and 
platelets of 121x109/L) with stable creatinine; his third loading dose of eculizumab was 
brought forward and this episode settled.   
He was maintained on eculizumab for 6 months, with adequate suppression of the alternative 
pathway (AH50 absent), although there was evidence of ongoing hemolysis (LDH above 
reference range and persistent anemia).  
Screening for complement abnormalities did not reveal any pathogenic variants in aHUS 
associated genes (CFH, CFI, CFB, C3, CD46, THBD, INF2 and DGKE) or factor H 
autoantibodies7. 
Six months after commencing eculizumab, he presented with a lower respiratory tract 
infection. Despite evidence of effective complement blockade (AH50 absent), he was found 
to have acute hemolysis (hemoglobin 51g/L and LDH 4890U/L) and thrombocytopenia 
(platelet 123 x109/L), without a change in serum creatinine. This settled spontaneously after 
treatment with intravenous antibiotics and a single blood transfusion.  
Due to eculizumab resistance with chronic hemolysis, we undertook whole exome 
sequencing (as previously described8) and identified a pathogenic variant in G6PD 
(c.1160G>A, pR387H). Functional erythrocyte G6PD activity levels confirmed severely 
depressed G6PD levels 0.4IU/1012 erythrocytes (4.5 – 13.5).  
Following the decision to discontinue eculizumab, at 3 months the patient had one relapse, 
again associated with metapneumovirus infection, which required a blood transfusion, but 
without a change in his renal function or complement levels (C3 0.96mg/L, C4 0.32mg/L).  
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At last follow-up, 3 years after discontinuation of eculizumab he has not suffered any further 
acute relapses, although he has persistent chronic hemolysis (raised LDH and decreased 
hemoglobin) requiring folate supplementation.  
Discussion 
G6PD deficiency typically presents with hemolysis provoked by infection or drugs without 
AKI or thrombocytopenia. The presence of these features in this case lead to a delay in the 
eventual diagnosis.  
Glucose 6 Phosphate dehydrogenase deficiency (MIM 134700) is an X-linked recessive 
condition, which occurs as a result of mutations in G6PD9 . G6PD is ubiquitously expressed10 
and catalyzes the conversion of glucose-6-phosphate to 6-phosphoglucono-δ-lactone 
generating NADPH, in the first step of the pentose phosphate pathway9. This is the sole 
NADPH source within erythrocytes and is required to maintain the redox state intracellularly 
and prevent damage from free radical and reactive oxygen species produced during cellular 
metabolism11.  
G6PD deficiency is classified (I to V) depending on enzyme activity12, with class I  variants 
representing the most severe deficiency (activity <10%). Most individuals with G6PD 
deficiency remain asymptomatic but are susceptible to acute hemolytic crisis, due to 
oxidative damage, precipitated by infections, drugs or eating fava beans9.  As with G6PD, 
primary complement mediated aHUS is frequently triggered by environmental stimuli. In 
addition to susceptibility to acute hemolytic crisis, individuals with class I variants suffer 
chronic non-spherocytic hemolytic anemia (CNSHA).  
Within erythrocytes, oxidative damage leads to the formation of neoepitopes on band 3 
protein on the cell membrane. This results in the binding of naturally occurring antibodies 
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and ultimately C3b deposition and opsonization13. Clearance of these cells is thought to be, at 
least in part, complement dependent, mediated by CR114. That hemolysis continued in this 
case, despite eculizumab indicates that the hemolysis and clearance of erythrocytes in G6PD 
is independent of the terminal pathway of complement. 
In vivo G6PD functions as a homodimer or tetramer15. The variant identified in this child, 
R387H, lies at this interface immediately adjacent to the β sheet strand “βL” (figure 2). This 
acts as a scaffold for both the dimer interface and NADP+ binding. This variant has been 
described in patients with CNSHA and in keeping with this, functional analysis has 
demonstrated severely reduced G6PD (class I) activity16. 
In this case, the patient presented with a clinical picture indistinguishable from aHUS, 
including AKI. AKI is a rare complication of acute hemolytic crisis in G6PD and is also seen 
in other hemolytic conditions such as paroxysmal nocturnal hemoglobinuria and sickle cell 
disease. Free hemoglobin released during hemolysis exceeds the binding capacity of 
haptoglobin, resulting in filtration of free hemoglobin and heme at the glomerulus. This leads 
to oxidative damage and apoptosis of the tubular cells with subsequent obstruction and acute 
tubular necrosis (ATN)17. Renal biopsies from patients with G6PD deficiency induced AKI, 
frequently demonstrate ATN18. Our patient has had one episode of AKI requiring dialysis; 
renal biopsy was not performed due to thrombocytopenia. His renal function has returned to 
baseline, without any evidence of chronic damage in keeping with a presumed diagnosis of 
ATN. 
Intriguingly, our patient developed thrombocytopenia during three of four acute hemolytic 
episodes, returning to normal when he was healthy. Mild thrombocytopenia has only rarely 
been reported during episodes of acute hemolytic crisis19, 20. Previous analysis has shown the 
activity of G6PD in platelets of patients with G6PD deficiency is severely reduced without an 
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appreciable effect on their function although increased platelet microparticles have been 
reported, especially in severe deficiency21.  R387H is one of the most severe variants in 
G6PD16;  and the thrombocytopenia in this case may be due to overwhelming oxidative 
stress.  
In summary, we report a child presenting with non-immune hemolysis, thrombocytopenia 
and AKI who did not respond to treatment with eculizumab. Using whole exome sequencing, 
we identified a pathological variant in G6PD that likely caused the phenotype that is 
clinically indistinguishable from aHUS. This demonstrates the utility of next generation 
sequencing techniques in cases where there may be diagnostic uncertainty, allowing 
personalized management of these clinical syndromes.   
G6PD is a rare but important differential diagnosis in patients presenting with an aHUS 
phenotype. The diagnosis of G6PD deficiency is most easily made by measuring reduced 
G6PD activity in erythrocytes. This test must be done whilst in remission, as there is a 
refractory period after acute hemolytic crisis where measured levels will be falsely elevated, 
as older erythrocytes with lower enzyme levels will be destroyed and only younger 
erythrocytes with higher residual G6PD levels are measured. We recommend testing for 
G6PD deficiency in aHUS patients, particularly in those who fail to respond to complement 
blockade, thus avoiding the risk and cost of long-term eculizumab treatment. 
Support: SJ and DK have received honoraria for consultancy work from Alexion 
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Figure Legends 
Figure 1 Clinical course  
Creatinine, LDH and platelet count plotted over the first 400 days following the initial 
presentation. Clinical interventions with plasma exchange (PEX) and eculizumab are shown 
above. Arrows demonstrate infectious triggers (HMPV- human metapneumovirus, LRTI- 
lower respiratory tract infection, PLT – Platelets, LDH – Lactate dehydrogenase).  
(Conversion factors: serum creatinine in μmol/L to mg/dL, ÷88.4) 
Figure 2. The location of the p.R387H mutation displayed on the G6PD homodimer 
structure.  
An x-ray–derived crystal structure of G6PD (1QKI) 15 was used to model the p.R387H 
mutation and displayed with Pymol (Delano Scientific). Individual monomers are shown in 
grey and green. The position of the bound structural NADP molecule is shown (black).  The 
location of the p.R387H mutation is highlighted as a red sphere. R387H lies immediately 
adjacent to the β sheet strand “βL” and the main chain atom is at the dimer surface. 
Additionally although the mutation is over 8 Å from the structural NADP+ the R387H 
function can be restored by addition of NADP+, suggesting that there is also interference with 
the structural NADP+ site resulting in destabilization of the G6PD homodimer12. 
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